

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Parkhill, J; Wren, BW; Thomson, NR; Titball, RW; Holden, MTG; Prentice, MB; Sebahia, M; James, KD; Churcher, C; Mungall, KL; +25 more... Baker, S; Basham, D; Bentley, SD; Brooks, K; Cerdeno-Tarraga, AM; Chillingworth, T; Cronin, A; Davies, RM; Davis, P; Dougan, G; Feltwell, T; Hamlin, N; Holroyd, S; Jagels, K; Karlyshev, AV; Leather, S; Moule, S; Oyston, PCF; Quail, M; Rutherford, K; Simmonds, M; Skelton, J; Stevens, K; Whitehead, S; Barrell, BG; (2001) Genome sequence of *Yersinia pestis*, the causative agent of plague. *Nature*, 413 (6855). pp. 523-527. ISSN 0028-0836 DOI: <https://doi.org/10.1038/35097083>

Downloaded from: <http://researchonline.lshtm.ac.uk/17397/>

DOI: <https://doi.org/10.1038/35097083>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-sa/2.5/>

<https://researchonline.lshtm.ac.uk>

24. Bennett, C. L. *et al.* The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nature Genet.* **27**, 20–21 (2001).
25. Brunkow, M. E. *et al.* Disruption of a new forkhead/winged-helix protein, scurf1, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nature Genet.* **27**, 68–73 (2001).
26. De Felice, M. *et al.* A mouse model for hereditary thyroid dysgenesis and cleft palate. *Nature Genet.* **19**, 395–398 (1998).
27. Smith, R. S. *et al.* Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. *Hum. Mol. Genet.* **9**, 1021–1032 (2000).
28. Lehmann, O. J. *et al.* Chromosomal duplication involving the forkhead transcription factor gene FOXC1 causes iris hypoplasia and glaucoma. *Am. J. Hum. Genet.* **67**, 1129–1135 (2000).
29. Nishimura, D. Y. *et al.* A spectrum of FOXC1 mutations suggests gene dosage as a mechanism for developmental defects of the anterior chamber of the eye. *Am. J. Hum. Genet.* **68**, 364–372 (2001).
30. Cummings, C. J. & Zoghbi, H. Y. Fourteen and counting: unraveling trinucleotide repeat diseases. *Hum. Mol. Genet.* **9**, 909–916 (2000).

Supplementary information is available on Nature's World-Wide Web site (<http://www.nature.com>) or as paper copy from the London editorial office of Nature.

Acknowledgements

We are deeply indebted to the KE family whose continued cooperation has made this research possible. We also thank CS and family for agreeing to participate in this study. We thank D. C. Jamison and E. D. Green for facilitating completion of the 7q31 genomic sequence; M. Fox, S. Jeremiah and S. Povey for the chromosome 7 hybrids; E. R. Levy for assistance with cytogenetic analyses; D. I. Stuart, E. Y. Jones and R. M. Esnouf for advice on structural analyses of forkhead domains; L. Rampoldi for assistance with northern blots; and E. Dunne for help with sequence analyses of other 7q31 candidate genes. Chromosome 7 sequence data were generated by the Washington University Genome Sequencing Center. This study was funded by the Wellcome Trust. A.P.M. is a Wellcome Trust Principal Research Fellow.

Correspondence and requests for materials should be addressed to A.P.M. (e-mail: anthony@well.ox.ac.uk).

Genome sequence of *Yersinia pestis*, the causative agent of plague

J. Parkhill*, **B. W. Wren†**, **N. R. Thomson***, **R. W. Titball‡**, **M. T. G. Holden***, **M. B. Prentice§**, **M. Sebahia***, **K. D. James***, **C. Churcher***, **K. L. Mungall***, **S. Baker***, **D. Basham***, **S. D. Bentley***, **K. Brooks***, **A. M. Cerdeño-Tarraga***, **T. Chillingworth***, **A. Cronin***, **R. M. Davies***, **P. Davis***, **G. Dougan||**, **T. Feltwell***, **N. Hamlin***, **S. Holroyd***, **K. Jagels***, **A. V. Karlyshev†**, **S. Leather***, **S. Moule***, **P. C. F. Oyston‡**, **M. Quail***, **K. Rutherford***, **M. Simmonds***, **J. Skelton***, **K. Stevens***, **S. Whitehead*** & **B. G. Barrell***

* The Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
 † Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
 ‡ Chemical and Biological Sciences, Dstl, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
 § Department of Medical Microbiology, St Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1A 7BE, UK
 || Centre for Molecular Microbiology and Infection, Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London SW7 2AZ, UK

The Gram-negative bacterium *Yersinia pestis* is the causative agent of the systemic invasive infectious disease classically referred to as plague¹, and has been responsible for three human pandemics: the Justinian plague (sixth to eighth centuries), the Black Death (fourteenth to nineteenth centuries) and modern plague (nineteenth century to the present day). The recent identification of strains resistant to multiple drugs² and the potential use of *Y. pestis* as an agent of biological warfare mean that plague still poses a threat to human health. Here we report the complete genome sequence of *Y. pestis* strain CO92, consisting of a 4.65-megabase (Mb) chromosome and three plasmids of 96.2 kilobases (kb), 70.3 kb and 9.6 kb. The genome is unusually rich

in insertion sequences and displays anomalies in GC base-composition bias, indicating frequent intragenomic recombination. Many genes seem to have been acquired from other bacteria and viruses (including adhesins, secretion systems and insecticidal toxins). The genome contains around 150 pseudogenes, many of which are remnants of a redundant enteropathogenic lifestyle. The evidence of ongoing genome fluidity, expansion and decay suggests *Y. pestis* is a pathogen that has undergone large-scale genetic flux and provides a unique insight into the ways in which new and highly virulent pathogens evolve.

Yersinia pestis is primarily a rodent pathogen, usually transmitted subcutaneously to humans by the bite of an infected flea, but also transmitted by air, especially during pandemics of disease. Notably, *Y. pestis* is very closely related to the gastrointestinal pathogen *Yersinia pseudotuberculosis*, and it has been proposed that *Y. pestis* is a clone that evolved from *Y. pseudotuberculosis* (probably serotype O:1b (ref. 3)) 1,500–20,000 years ago⁴. Thus *Y. pestis* seems to have rapidly adapted from being a mammalian enteropathogen widely found in the environment, to a blood-borne pathogen of mammals that is also able to parasitize insects and has limited capability for survival outside these hosts. Horizontally acquired DNA may be significant in having enabled *Y. pestis* to adapt to new hosts; conversely, the identification of gene remnants produced through genome decay may be associated with a redundant enteric lifestyle. Given the historical importance of plague and the need to understand the evolution and pathogenesis of such a potentially devastating pathogen, we undertook the genome sequencing of *Y. pestis* CO92 (biovar Orientalis), a strain recently isolated from a fatal human case of primary pneumonic plague contracted from an infected cat⁵.

The general features of the genome are shown in Fig. 1 and Table 1. The most striking large-scale features in the genome are anomalies in GC bias. All bacterial genomes sequenced to date have a small but detectable bias towards G on the leading strand of the bidirectional replication fork⁶. Anomalies in this plot can be caused by the very recent acquisition of DNA (such as prophages) or by the inversion or translocation of blocks of DNA. The three anomalies visible in the *Y. pestis* plot (see Supplementary Information; see also http://www.sanger.ac.uk/Projects/Y_pestis/) are each bounded by insertion sequence elements, suggesting that they could be the result of recent recombination between these perfect repeats. To investigate this, we designed polymerase chain reaction (PCR) primers to test for the presence and absence of the predicted translocation, and for the orientation of the two inversions (see Supplementary Information). PCR confirmed the position of the translocation, but, intriguingly, the results for the two inversions showed that both orientations were present in the same DNA preparation, with the inverse orientation predominating. This suggests genomic rearrangement during growth of the organism. The results were similar in DNA from three different subcultures of CO92 and investigation of other strains indicated that similar rearrangements may have occurred (see Supplementary Information). These results demonstrate that the *Y. pestis* genome is fluid, and capable of frequent intragenomic recombination *in vitro*; the rapid emergence of new ribotypes of *Y. pestis* biovar Orientalis in the environment following pandemic spread⁷ shows that chromosomal rearrangements are common *in vivo*. The effects of these rearrangements on the biology and pathogenicity of the organism are unknown.

Gene acquisition has been important in the evolution of *Y. pestis*. In addition to the 70-kb virulence plasmid (pYV/pCD1) found in all pathogenic *Yersinia*, *Y. pestis* has acquired two unique plasmids that encode a variety of virulence determinants. A 9.5-kb plasmid (pPst/pPCP1) encodes the plasminogen activator Pla (ref. 8), a putative invasin that is essential for virulence by the subcutaneous route. A 100–110-kb plasmid (pFra/pMT1) encodes murine toxin Ymt and the F1 capsular protein, which have been shown to have a role in the transmission of plague. No conjugation apparatus is

encoded by any *Yersinia* plasmid, but horizontal mobility has apparently occurred: a plasmid closely related to pFra (but lacking *ymt* and the *caf* operon) exists in the exclusively human pathogen *Salmonella enterica* serovar Typhi⁹.

Many regions within the *Y. pestis* chromosome showed some of the characteristics of islands acquired through lateral transfer (see Supplementary Information). Among these were several genes that seem to have come from other insect pathogens. Only two features of *Y. pestis* have so far been shown to be essential for aspects of its life cycle in the flea: the plasmid-encoded murine toxin Ymt is essential for flea colonization¹⁰, and the chromosomal

hms locus is required for blockage of the flea midgut by *Y. pestis* to maximize its transmission¹. This second locus is also present in *Y. pseudotuberculosis*¹¹.

Sequences related to the parasitism of insects include genes encoding homologues of the insecticidal toxin complexes (Tcs) from *Photobacterium luminescens*, *Serratia entomophila* and *Xenorhabdus nematophilus*¹². These toxins are complexes of the products of three different gene families: *tcaA/tcaB/tcdA*, *tcaC/tcdB* and *tccC*. In *Y. pestis*, three adjacent genes encoding homologues of *P. luminescens* TcaA, TcaB and TcaC were identified (YPO3681, 35% identity; YPO3679, 42% identity; and YPO3678,




Figure 1 Circular representation of the *Y. pestis* genome. The outer scale is marked in megabases. Circles 1 and 2 (from the outside in), all genes colour coded by function, forward and reverse strand; circles 3 and 4, pseudogenes; circles 5 and 6, insertion sequence elements (blue, IS1661; black, IS285; red, IS1541; green, IS100); circle 7, G + C content (higher values outward); circle 8, GC bias ((G - C/G + C), khaki indicates values >1, purple <1). Colour coding for genes: dark blue, pathogenicity or adaptation;

black, energy metabolism; red, information transfer; dark green, surface associated; cyan, degradation of large molecules; magenta, degradation of small molecules; yellow, central or intermediary metabolism; pale blue, regulators; orange, conserved hypothetical; brown, pseudogenes; pink, phage and insertion sequence elements; pale green, unknown; grey, miscellaneous.

Table 1 General features of the *Yersinia pestis* genome

	Chromosome	pPst/pPCP1	pYV1/pCD1	pFra/pMT1
Estimated copy number*		186	4.3	1.8
Total size	4,653,728 bp	9,612 bp	70,305 bp	96,210 bp
G + C content	47.64%	45.27%	44.84%	50.23%
Coding sequences	4,012	9	97	103
... of which pseudogenes	149	0	8	3
Coding density	83.8%	57.2%	81.4%	86.8%
Average gene length	998 bp	611 bp	643 bp	835 bp
Ribosomal RNAs	6 × (16S–23S–5S)			
Transfer RNAs	70			
Other stable RNAs	6			

*The copy number of the plasmids was estimated on the number of reads per kilobase compared with the chromosome, and is likely to be affected by sampling bias in the shotgun.

49% identity) separated from nearby homologues of TccC (YPO3673, 52% identity; and YPO3674, 54% identity) by phage-related genes. The *tcaA* gene was intact, but *tcaB* contained a frameshift mutation and *tcaC* an internal deletion. The disruption of these genes might be necessary for the lifestyle of *Y. pestis*, which persists in the flea gut for relatively long periods. Two isolated genes encoding homologues of TccC were also present in the genome (YPO2312, 60% identity; and YPO2380, 74% identity). Strikingly, a protein showing weak, but significant, similarity only to the enhancins encoded uniquely by baculoviral pathogens of insects was identified (YPO0339, 25% identity) in a region of low G + C content, flanked by a transfer RNA gene and transposase fragments, suggesting horizontal acquisition. During baculoviral pathogenesis, the proteolytic activity of enhancin damages the peritrophic membrane, which normally provides a physical barrier against microbial pathogens in the insect midgut¹³ and the product of YPO0339 may be important in colonization of the flea by *Y. pestis*. Interestingly,

PCR shows (R.W.T., data not shown) that the *tca* insecticidal toxin genes are also present in *Y. pseudotuberculosis* IP 32953 (virulent serotype I strain). This suggests an association between *Y. pseudotuberculosis* and insects, or insect pathogens in the environment, before the emergence of *Y. pestis*.

The type III secretion system located on the *Yersinia* virulence plasmid (pYV/pCD1) is present in all three human pathogenic species of *Yersinia*. This system allows translocation of a range of effector proteins (Yops) that downregulate the responses of host phagocytic cells to infection. Human pathogenic *Yersinia* possessing mutations that disrupt this system are severely attenuated¹⁴. A second chromosomally encoded type III secretion system, similar in gene content and order to the SPI-2 type III system of *Salmonella typhimurium*¹⁵, is also present in *Y. pestis* (Fig. 2). This secretion system is distinct from the chromosomally borne type III system in *Y. enterocolitica*¹⁶. We were unable to identify the effectors for this system, as these are generally divergent.

The genome sequence of *Y. pestis* CO92 also revealed the presence of a range of genes predicted to encode previously unknown surface antigens, which might have a role in the virulence of the bacterium. Two fimbrial-type surface structures were known in *Y. pestis*: the locus encoding pH6 antigen (*psa*) is chromosomally borne and is also found in *Y. pseudotuberculosis*, and the *caf* locus, encoding the F1 antigen, is found only in *Y. pestis* on plasmid pFra. We also identified eight systems with a similar organization to the *psa* and *caf* operons, each of which provides potential mechanisms for fimbrial or adhesin production (Fig. 2). In five cases the operons are flanked by genes encoding transposases or integrases, again implying horizontal acquisition. Such high redundancy of fimbria-related genes is also found in other bacterial pathogens, including




Figure 2 Protein secretion systems in *Y. pestis*. **a**, Chaperone–usher systems. The plasmid pMT1-borne *caf* system and nine chromosomal systems are shown. Blue, chaperones; red, usher proteins; green, putative target proteins; black, regulatory proteins; pink, transposases and integrases; brown, other genes. IS, insertion sequence element; FS, frameshift. **b**, Type III secretion systems. The chromosomal

and plasmid type III systems are shown, with *S. typhimurium* SPI-2 as a comparator. **c**, Flagella operons. The parts of the flagella clusters with similarity to type III systems are shown, with the *E. coli* flagella cluster as a comparator. The genes are arbitrarily colour coded in **b** and **c** to show related genes.

Escherichia coli and *Salmonella enterica* serovar Typhi¹⁷. A large arsenal of independent gene clusters encoding different fimbriae and adhesins might be beneficial in evading host immune response, or may allow multiple interactions with several different hosts during its complex life cycle.

Although there is ample evidence of horizontal gene acquisition, many of these sequences will have been acquired before *Y. pestis* evolved from *Y. pseudotuberculosis*. Preliminary comparisons with the unfinished *Y. pseudotuberculosis* sequence from the Lawrence Livermore National Laboratories (<http://bbbrp.llnl.gov/bbrp/html/microbe.html>) indicate that around 40% of the islands identified may be partially or completely absent from *Y. pseudotuberculosis*, although this must be treated with caution, given the incomplete nature of the data. Phylogenetic analysis to accurately date the acquisition of these genetic islands will have to await the completion of the genome sequences of *Y. pseudotuberculosis* and *Y. enterocolitica*.

Horizontal gene acquisition in *Y. pestis* has been balanced by gene loss. In total the genome sequence contains 149 pseudogenes, of which 51 are a consequence of disruption by insertion sequence elements. The total number of insertion sequences exceeds that described in most other bacterial genomes, comprising 3.7% of the genome. At least four different insertion sequences (IS) were found on the chromosome: 66 complete or partial copies of IS1541, 44 of IS100, 21 of IS285 and 9 of IS1661. Overall numbers of insertion sequence copies are around tenfold higher than in *Y. pseudotuberculosis* (IS1541, 7–13 copies¹⁸; IS100, 0–6 copies¹⁹). Fifty-eight pseudogenes were due to frameshift mutations (21 at homopolymeric tracts), 32 due to deletions, and the remainder due to in-frame stop codons. Mutations in genes associated with pathogenicity were over-represented (see Supplementary Information). Plasmid pCD1, which is shared with the enteropathogens *Y. enterocolitica* and *Y. pseudotuberculosis*, contained mutations in virulence-related genes *ylpA* and *yadA*, and in five other genes, but of the unique *Y. pestis* plasmids, pMT1 has only two pseudogenes and pPst has none.

The change in lifestyle of *Y. pestis* compared with the ancestral *Y. pseudotuberculosis* strain would be expected to result in the loss of genes required for enteropathogenicity. Enteropathogens specifically adhere to surfaces of the gut and may invade cells lining it. Proteins important for this process in *Y. pseudotuberculosis* include YadA and Invasin, both of which are represented by pseudogenes in *Y. pestis* (see Supplementary Information). Several of the other pseudogenes reported here could encode adhesin molecules, suggesting that some of these might also have been required for enteropathogenicity. The pseudogene YPO1562 shows 34% amino-acid identity with *E. coli* intimin, which is carried on a pathogenicity island termed the locus of enterocyte effacement. *Yersinia pseudotuberculosis* also contains an intact gene sharing 61% amino-acid identity with a further *E. coli* virulence factor, cytotoxic necrotizing factor 1 (CNF1); this is also represented by a pseudogene (YPO1449) in *Y. pestis*. CNF1 acts on Rho GTPases to affect cytoskeletal rearrangement²⁰, which may be required for epithelial invasion.

Thirty-eight (26%) of the pseudogenes would have encoded or synthesized surface-expressed antigens or exported proteins. Several mucosal pathogens have been shown to switch surface-expressed antigens on or off *in vitro* and *in vivo* using slipped-strand mispairing of repeat sequences during replication²¹. A similar process has been demonstrated in *Y. pestis*. The organism is characteristically urease negative but activity can be restored *in vitro* by the spontaneous deletion of a single base pair in a homopolymeric tract in *ureD*²². This type of reversible mutation would reduce the metabolic burden of producing proteins unnecessary to *Y. pestis* in its new flea/mammal life cycle yet still allow the potential to express these should a subsequent need arise.

Some typical virulence properties of enteropathogens are asso-

ciated with systems that in *Y. pestis* are subject to multiple mutations which would make reversion unlikely. Motility is required for efficient invasion of host cells by *Y. enterocolitica*²³, apparently by promoting bacterial contact with the host cell; strains of *Y. pestis* are uniformly nonmotile, and analysis of the flagellar and chemotaxis gene clusters reveal six mutations. However, there are two separate and distinct flagellar gene clusters (Fig. 2), one of which contains no obvious mutations in flagellar biosynthetic or structural genes, suggesting that some form of motility may be possible under as-yet-undiscovered conditions.

Five pseudogenes were lipopolysaccharide (LPS) biosynthesis genes. The O side chain of LPS is an important factor in the virulence of a range of pathogens, including *Y. enterocolitica*²⁴. The O side chain mediates resistance to complement-mediated and phagocyte killing. It might also have a role in survival in the gut by protecting the bacterium from cationic peptides, such as those produced by Paneth cells in the human small intestine²⁵. *Yersinia pestis* produces a rough LPS, lacking an O antigen as a consequence of these mutations within the biosynthesis cluster of the O antigen³, but the nature of the selective advantage this may confer to *Y. pestis* is unexplained. The surface adhesin Ail (YPO2905) is also involved in serum resistance in *Y. enterocolitica*²⁶. An IS285 insertion was reported in the *ail* gene of a laboratory-adapted strain of *Y. pestis* used as a vaccine²⁷, and *ail* is generally assumed to be inactivated in *Y. pestis*⁸. However, in strain CO92 it is intact. Three other intact genes encoding different Ail-like proteins were identified (YPO1850, YPO2190, YPO2506); *Y. pestis* expresses an unidentified plasmid-independent adhesin⁸ that could therefore be Ail or a paralogue. Rough mutants of *Y. enterocolitica* show an enhanced ability to invade cultured cells, a suggested consequence of the enhanced accessibility of surface Ail²⁸. However, a recent mutagenesis study in *Y. pseudotuberculosis* found that O-antigen mutants were unable to invade epithelial cells²⁹ and were attenuated when infecting mice both orally and systemically, suggesting that as *Y. pestis* is invasive⁸ and virulent, it may have alternative surface structures that complement the loss of the O antigen.

Mutations in energy metabolism and central and intermediary metabolism are comparatively rare (see Supplementary Information). A mutation in the methionine biosynthetic pathway, and in *pheA*, may account for known requirements for growth *in vitro* of one or more of the amino acids cysteine, methionine and phenylalanine¹. In contrast, many of the mutations were in uptake and transport systems, indicating that, compared with life as a gastrointestinal pathogen, fewer or different types of nutrients are available to *Y. pestis* within the flea or mammal. Three isolated genes possibly involved in iron uptake and a gene essential for aerobactin production (*iucA*, YPO0989) are inactivated in *Y. pestis* CO92. However, adding to previously described iron-uptake systems, we identified three apparently functional siderophore biosynthesis operons, five siderophore uptake systems, a non-siderophore iron-uptake system and a second haem-acquisition system.

Several mechanisms account for the accumulation of pseudogenes in *Y. pestis*, including expansion of insertion sequence elements, deletion, point mutation and slippage in homopolymeric tracts. Together, these have resulted in the loss of genes that were either not required in its new niche, or may have decreased fitness for a new lifestyle as a systemic pathogen of mammals and an insect pathogen. Comparison of the pseudogenes (excluding those in insertion sequences and phages) with the unfinished *Y. pseudotuberculosis* sequence (see above) shows that, of the >60% for which information is available, >95% of the *Y. pseudotuberculosis* orthologues do not carry the inactivating mutation. This, combined with the published evidence of intact genes in *Y. pseudotuberculosis* detailed above, indicates that most of the mutations in *Y. pestis* are recent. They may have arisen in a gradual process since the colonization of this new niche, or *Y. pestis* could have acquired these pseudogenes as a consequence of an evolutionary bottleneck that

may have accompanied the colonization process.

The genome sequence of *Y. pestis* reveals a pathogen that has undergone considerable genetic flux, with evidence of selective genome expansion by lateral gene transfer of plasmid and chromosomal genes, and subsequent initial stages of genome size reduction. We believe that these features correlate with a change in pathogenic niche, and therefore this genome sequence provides a unique insight into the genetic events that are associated with the emergence of a new pathogenic species. The newly emerged pathogen is highly virulent for humans, causing pandemics of systemic, and often fatal, disease, contrasting with the ancestral species that evolved to cause non-fatal enteritis in similar hosts. □

Methods

A single colony of *Y. pestis* strain CO92 was picked from Congo Red agar and grown overnight in BAB broth with shaking at 37 °C. Cells were collected and total DNA (10 mg) was isolated using proteinase K treatment followed by phenol extraction. The DNA was fragmented by sonication, and several libraries were generated in pUC18 using size fractions ranging from 1.0 to 2.5 kb. The whole genome sequence was obtained from 94,881 end sequences (giving 9.6x coverage) derived from these libraries using dye terminator chemistry on ABI377 automated sequencers. End sequences from larger insert plasmid (pSP64; 3.1x clone coverage, 9–11 kb insert size) and lambda (lambda-FIX-1I; 4.0x clone coverage, 20–22 kb insert size) libraries were used as a scaffold. The sequence was assembled, finished and annotated as described previously³⁰, using the program Artemis (<http://www.sanger.ac.uk/Software/Artemis>) to collate data and facilitate annotation. The genome sequences of *Y. pestis* and *E. coli* were compared pairwise using the Artemis Comparison Tool (ACT) (<http://www.sanger.ac.uk/Software/ACT>). Pseudogenes had one or more mutations that would ablate expression; each of the inactivating mutations was subsequently checked against the original sequencing data.

Received 8 May; accepted 16 August 2001.

1. Perry, R. D. & Fetherston, J. D. *Yersinia pestis*—etiologic agent of plague. *Clin. Microbiol. Rev.* **10**, 35–66 (1997).
2. Galimand, M. *et al.* Multidrug resistance in *Yersinia pestis* mediated by a transferable plasmid. *N. Engl. J. Med.* **337**, 677–680 (1997).
3. Skurmik, M., Peippo, A. & Ervela, E. Characterization of the O-antigen gene clusters of *Yersinia pseudotuberculosis* and the cryptic O-antigen gene cluster of *Yersinia pestis* shows that the plague bacillus is most closely related to and has evolved from *Y. pseudotuberculosis* serotype O:1b. *Mol. Microbiol.* **37**, 316–330 (2000).
4. Achtman, M. *et al.* *Yersinia pestis*, the cause of plague, is a recently emerged clone of *Yersinia pseudotuberculosis*. *Proc. Natl Acad. Sci. USA* **96**, 14043–14048 (1999).
5. Doll, J. M. *et al.* Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. *Am. J. Trop. Med. Hyg.* **51**, 109–114 (1994).
6. Lobry, J. R. Asymmetric substitution patterns in the two DNA strands of bacteria. *Mol. Biol. Evol.* **13**, 660–665 (1996).
7. Guiyoule, A. *et al.* Recent emergence of new variants of *Yersinia pestis* in Madagascar. *J. Clin. Microbiol.* **35**, 2826–2833 (1997).
8. Cowan, C., Jones, H. A., Kaya, Y. H., Perry, R. D. & Straley, S. C. Invasion of epithelial cells by *Yersinia pestis*: evidence for a *Y. pestis*-specific invasin. *Infect. Immun.* **68**, 4523–4530 (2000).
9. Prentice, M. B. *et al.* *Yersinia pestis* pFra shows biovar-specific differences and recent common ancestry with a *Salmonella enterica* serovar Typhi plasmid. *J. Bacteriol.* **183**, 2586–2594 (2001).
10. Hinnebusch, J. *et al.* Murine toxin of *Yersinia pestis* shows phospholipase D activity but is not required for virulence in mice. *Int. J. Med. Microbiol.* **290**, 483–487 (2000).
11. Buchrieser, C. *et al.* The 102-kilobase *pgm* locus of *Yersinia pestis*: sequence analysis and comparison of selected regions among different *Yersinia pestis* and *Yersinia pseudotuberculosis* strains. *Infect. Immun.* **67**, 4851–4861 (1999).
12. Waterfield, N. R., Bowen, D. J., Fetherston, J. D., Perry, R. D. & French-Constant, R. H. The *tc* genes of *Photobacterium*: a growing family. *Trends Microbiol.* **9**, 185–191 (2001).
13. Wang, P. & Granados, R. R. An intestinal mucin is the target substrate for a baculovirus enhancer. *Proc. Natl Acad. Sci. USA* **94**, 6977–6982 (1997).
14. Cornelis, G. R. *et al.* The virulence plasmid of *Yersinia*, an antihost genome. *Microbiol. Mol. Biol. Rev.* **62**, 1315–1352 (1998).
15. Shea, J. E., Hensel, M., Gleeson, C. & Holden, D. W. Identification of a virulence locus encoding a second type III secretion system in *Salmonella typhimurium*. *Proc. Natl Acad. Sci. USA* **93**, 2593–2597 (1996).
16. Haller, J. C., Carlson, S., Pederson, K. J. & Pierson, D. E. A chromosomally encoded type III secretion pathway in *Yersinia enterocolitica* is important in virulence. *Mol. Microbiol.* **36**, 1436–1446 (2000).
17. Townsend, S. M. *et al.* *Salmonella enterica* serovar Typhi possesses a unique repertoire of fimbrial gene sequences. *Infect. Immun.* **69**, 2894–2901 (2001).
18. Odaert, M., Berche, P. & Simonet, M. Molecular typing of *Yersinia pseudotuberculosis* by using an IS200-like element. *J. Clin. Microbiol.* **34**, 2231–2235 (1996).
19. McDonough, K. A. & Hare, J. M. Homology with a repeated *Yersinia pestis* DNA sequence IS100 correlates with pesticin sensitivity in *Yersinia pseudotuberculosis*. *J. Bacteriol.* **179**, 2081–2085 (1997).
20. Lerm, M., Schmidt, G. & Aktories, K. Bacterial protein toxins targeting rho GTPases. *FEMS Microbiol. Lett.* **188**, 1–6 (2000).
21. Henderson, I. R., Owen, P. & Nataro, J. P. Molecular switches—the ON and OFF of bacterial phase variation. *Mol. Microbiol.* **33**, 919–932 (1999).
22. Sebbane, F., Devalckenaere, A., Foulon, J., Carniel, E. & Simonet, M. Silencing and reactivation of urease in *Yersinia pestis* is determined by one G residue at a specific position in the *ureD* gene. *Infect. Immun.* **69**, 170–176 (2001).
23. Young, G. M., Badger, J. L. & Miller, V. L. Motility is required to initiate host cell invasion by *Yersinia*

- enterocolitica*. *Infect. Immun.* **68**, 4323–4326 (2000).
24. Darwin, A. J. & Miller, V. L. Identification of *Yersinia enterocolitica* genes affecting survival in an animal host using signature-tagged transposon mutagenesis. *Mol. Microbiol.* **32**, 51–62 (1999).
25. Nesper, J. *et al.* Characterization of *Vibrio cholerae* O1 El Tor *galU* and *galE* mutants: influence on lipopolysaccharide structure, colonization, and biofilm formation. *Infect. Immun.* **69**, 435–445 (2001).
26. Wachtel, M. R. & Miller, V. L. *In vitro* and *in vivo* characterization of an *ail* mutant of *Yersinia enterocolitica*. *Infect. Immun.* **63**, 2541–2548 (1995).
27. Torosian, S. & Zsigray, R. In *Abstracts of the 96th General Meeting of the American Society of Microbiology 1996* Abstract B-13, 191 (American Society for Microbiology, Washington DC, 1996).
28. Pierson, D. E. Mutations affecting lipopolysaccharide enhance *ail*-mediated entry of *Yersinia enterocolitica* into mammalian cells. *J. Bacteriol.* **176**, 4043–4051 (1994).
29. Mecas, J., Bilis, I. & Falkow, S. Identification of attenuated *Yersinia pseudotuberculosis* strains and characterization of an orogastric infection in BALB/c mice on day 5 postinfection by signature-tagged mutagenesis. *Infect. Immun.* **69**, 2779–2787 (2001).
30. Parkhill, J. *et al.* Complete DNA sequence of a serogroup A strain of *Neisseria meningitidis* Z2491. *Nature* **404**, 502–506 (2000).

Supplementary information is available on Nature’s World-Web site (<http://www.nature.com>) or as paper copy from the London editorial office of Nature.

Acknowledgements

We acknowledge the support of the Sanger Centre core sequencing, subcloning and informatics groups. This work was funded by the Wellcome Trust through its Beowulf Genomics initiative. We are grateful to E. Garcia of the *Y. pseudotuberculosis* sequencing group at the Lawrence Livermore National Laboratories for giving permission to use sequence data before they are published. B.W.W. and A.V.K. are supported by the Wellcome Trust.

Correspondence and requests for materials should be addressed to J.P. (e-mail: parkhill@sanger.ac.uk) or B.W.W. (e-mail: brendan.wren@lshtm.ac.uk). The sequences have been submitted to EMBL under the accession numbers AL590842 (chromosome), AL109969 (pPCP1), AL117189 (pCD1) and AL117211 (pMT1).

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

David Panikashvili*†, Constantina Simeonidou*, Shimon Ben-Shabat†, Lumir Hanuš†, Aviva Breuer†, Raphael Mechoulam† & Esther Shohami*

* Department of Pharmacology, and † Department of Medicinal Chemistry and Natural Products, Medical Faculty, Hebrew University, Jerusalem 91120, Israel

Traumatic brain injury triggers the accumulation of harmful mediators that may lead to secondary damage^{1,2}. Protective mechanisms to attenuate damage are also set in motion². 2-Arachidonoyl glycerol (2-AG) is an endogenous cannabinoid, identified both in the periphery³ and in the brain⁴, but its physiological roles have been only partially clarified^{5–7}. Here we show that, after injury to the mouse brain, 2-AG may have a neuroprotective role in which the cannabinoid system is involved. After closed head injury (CHI) in mice, the level of endogenous 2-AG was significantly elevated. We administered synthetic 2-AG to mice after CHI and found significant reduction of brain oedema, better clinical recovery, reduced infarct volume and reduced hippocampal cell death compared with controls. When 2-AG was administered together with additional inactive 2-acyl-glycerols that are normally present in the brain, functional recovery was significantly enhanced. The beneficial effect of 2-AG was dose-dependently attenuated by SR-141761A, an antagonist of the CB₁ cannabinoid receptor.

Traumatic brain injury is a major cause of mortality and morbidity, yet there is no effective drug to treat brain-injured patients. Understanding post-trauma events and developing neuroprotective agents are therefore important⁸. Cannabinoids act through two distinct receptors, one of which (CB₁) is found mainly in the brain. We have previously reported that 2-AG suppresses formation of reactive oxygen species (ROS) and tumour necrosis factor-α (TNF-α) by murine macrophages